153 related articles for article (PubMed ID: 21922332)
1. In vivo electroporation restores the low effectiveness of DNA vaccination against HER-2/neu in aging.
Provinciali M; Barucca A; Pierpaoli E; Orlando F; Pierpaoli S; Smorlesi A
Cancer Immunol Immunother; 2012 Mar; 61(3):363-71. PubMed ID: 21922332
[TBL] [Abstract][Full Text] [Related]
2. DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice.
Curcio C; Khan AS; Amici A; Spadaro M; Quaglino E; Cavallo F; Forni G; Draghia-Akli R
Cancer Gene Ther; 2008 Feb; 15(2):108-14. PubMed ID: 17992201
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of different plasmid DNA delivery systems for immunization against HER2/neu in a transgenic murine model of mammary carcinoma.
Smorlesi A; Papalini F; Amici A; Orlando F; Pierpaoli S; Mancini C; Provinciali M
Vaccine; 2006 Mar; 24(11):1766-75. PubMed ID: 16288939
[TBL] [Abstract][Full Text] [Related]
4. Low effectiveness of DNA vaccination against HER-2/neu in ageing.
Provinciali M; Smorlesi A; Donnini A; Bartozzi B; Amici A
Vaccine; 2003 Feb; 21(9-10):843-8. PubMed ID: 12547592
[TBL] [Abstract][Full Text] [Related]
5. Booster immunizations with DNA plasmids encoding HER-2/neu prevent spontaneous mammary cancer in HER-2/neu transgenic mice over life span.
Provinciali M; Barucca A; Orlando F; Pierpaoli E
Sci Rep; 2017 Jun; 7(1):3078. PubMed ID: 28596550
[TBL] [Abstract][Full Text] [Related]
6. HER2/neu DNA vaccination for breast tumors.
Smorlesi A; Papalini F; Pierpaoli S; Provinciali M
Methods Mol Biol; 2008; 423():473-85. PubMed ID: 18370223
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination.
Pupa SM; Iezzi M; Di Carlo E; Invernizzi A; Cavallo F; Meazza R; Comes A; Ferrini S; Musiani P; Ménard S
Cancer Res; 2005 Feb; 65(3):1071-8. PubMed ID: 15705909
[TBL] [Abstract][Full Text] [Related]
8. Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity.
Jacob JB; Kong YC; Nalbantoglu I; Snower DP; Wei WZ
J Immunol; 2009 May; 182(9):5873-81. PubMed ID: 19380836
[TBL] [Abstract][Full Text] [Related]
9. CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC.
Nguyen-Hoai T; Hohn O; Vu MD; Baldenhofer G; Sayed Ahmed MS; Dörken B; Norley S; Lipp M; Pezzutto A; Westermann J
Cancer Gene Ther; 2012 Dec; 19(12):880-7. PubMed ID: 23099886
[TBL] [Abstract][Full Text] [Related]
10. Intradermal DNA Electroporation Induces Cellular and Humoral Immune Response and Confers Protection against HER2/neu Tumor.
Lamolinara A; Stramucci L; Hysi A; Iezzi M; Marchini C; Mariotti M; Amici A; Curcio C
J Immunol Res; 2015; 2015():159145. PubMed ID: 26247038
[TBL] [Abstract][Full Text] [Related]
11. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector.
Gallo P; Dharmapuri S; Nuzzo M; Maldini D; Iezzi M; Cavallo F; Musiani P; Forni G; Monaci P
Int J Cancer; 2005 Jan; 113(1):67-77. PubMed ID: 15386429
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice.
Gallo P; Dharmapuri S; Nuzzo M; Maldini D; Cipriani B; Forni G; Monaci P
Int J Cancer; 2007 Feb; 120(3):574-84. PubMed ID: 17096348
[TBL] [Abstract][Full Text] [Related]
13. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice.
Rovero S; Amici A; Di Carlo E; Bei R; Nanni P; Quaglino E; Porcedda P; Boggio K; Smorlesi A; Lollini PL; Landuzzi L; Colombo MP; Giovarelli M; Musiani P; Forni G
J Immunol; 2000 Nov; 165(9):5133-42. PubMed ID: 11046045
[TBL] [Abstract][Full Text] [Related]
14. CCL4 as an adjuvant for DNA vaccination in a Her2/neu mouse tumor model.
Nguyen-Hoai T; Pham-Duc M; Gries M; Dörken B; Pezzutto A; Westermann J
Cancer Gene Ther; 2016 Jun; 23(6):162-7. PubMed ID: 27056671
[TBL] [Abstract][Full Text] [Related]
15. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.
Jacob J; Radkevich O; Forni G; Zielinski J; Shim D; Jones RF; Wei WZ
Cell Immunol; 2006 Apr; 240(2):96-106. PubMed ID: 16930573
[TBL] [Abstract][Full Text] [Related]
16. Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2.
Piechocki MP; Pilon SA; Wei WZ
J Immunol; 2001 Sep; 167(6):3367-74. PubMed ID: 11544327
[TBL] [Abstract][Full Text] [Related]
17. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice.
Quaglino E; Iezzi M; Mastini C; Amici A; Pericle F; Di Carlo E; Pupa SM; De Giovanni C; Spadaro M; Curcio C; Lollini PL; Musiani P; Forni G; Cavallo F
Cancer Res; 2004 Apr; 64(8):2858-64. PubMed ID: 15087404
[TBL] [Abstract][Full Text] [Related]
18. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
Wang X; Wang JP; Rao XM; Price JE; Zhou HS; Lachman LB
Breast Cancer Res; 2005; 7(5):R580-8. PubMed ID: 16168101
[TBL] [Abstract][Full Text] [Related]
19. CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model.
Nguyen-Hoai T; Baldenhofer G; Sayed Ahmed MS; Pham-Duc M; Vu MD; Lipp M; Dörken B; Pezzutto A; Westermann J
Cancer Gene Ther; 2012 Jan; 19(1):69-76. PubMed ID: 21997231
[TBL] [Abstract][Full Text] [Related]
20. Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen.
Bråve A; Hallengärd D; Gudmundsdotter L; Stout R; Walters R; Wahren B; Hallermalm K
Vaccine; 2009 Jun; 27(28):3692-6. PubMed ID: 19428161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
